Inclusion Criteria:  Age ≥ 65 years Symptomatic severe aortic stenosis defined by an aortic valve area (AVA) ≤1.0 cm2 or an AVA indexed to body surface area <0.6cm2/m2 Selected to undergo transfemoral TAVI based on heart team decision  Exclusion Criteria:  Life expectancy <1 year irrespective of valvular heart disease Kidney disease with a creatinine clearance ≤30 ml/min Known severe liver disease Known neuromuscular disease Clinically significant anaemia with haemoglobin <80g/L Known inflammatory bowel disease or chronic diarrhea Known ongoing bacterial infection Known galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption Current treatment with colchicine, steroids or biologicals for any indication Concomitant intake of Cyclosporine, Amiodarone, Clarithromycin, Erythromycin, Omeprazole, Verapamil or other strong inhibitors of CYP3A4 or P-Glycoprotein Concomitant intake of Carbamazepin, Phenobarbital, Phenytoin, Rifampicin or other strong inductors of CYP3A4 and P-Glycoprotein Permanent pacemaker or implantable cardioverter defibrillator History of atrial fibrillation Absence of sinus rhythm on hospital admission Planned non-cardiac surgery within 30 days Known intolerance to colchicine Inability to provide written informed consent Known or suspected non-compliance, drug or alcohol abuse Participation in another clinical trial with an active intervention Any other planned cardiac intervention performed in the 7 days before TAVI, concomitantly with TAVI or in the 30 days after TAVI except for percutaneous coronary interventions.